Investigational T2 Diabetes Drug May Have Fewer Side EffectsFriday, June 29, 2012
Drugs for type 2 diabetes can contribute to weight gain, bone fractures and cardiovascular problems, but in mice, an investigational drug appears to improve insulin sensitivity without those troublesome side effects, researchers at Washington University School of Medicine in St. Louis have shown.
The experimental medicine works through a different pathway, which could provide additional molecular targets for treating insulin resistance and diabetes. The new study appears online in the Journal of Biological Chemistry.
“Current diabetes medications activate a receptor that improves insulin sensitivity, but unfortunately also contributes to side effects that make some people discontinue the medication, contributing to other health problems,” says principal investigator Brian N. Finck, PhD. “So even though these drugs are effective, we’d really like to find new insulin-sensitizing therapies that would avoid activating the same receptor.”
Finck, a research assistant professor of medicine in the Division of Geriatrics and Nutritional Science, worked with colleagues at the University of Michigan and at the drug discovery company Metabolic Solutions Development Co., LLC. The scientists studied one of the company’s investigational drugs, MSD-0602, focusing on its effects in obese mice.
The drug improved blood glucose levels and insulin tolerance in the mice, as did the two diabetes drugs that already are on the market: rosiglitazone (Avandia) and pioglitazone (Actos). All three medications appeared to be about equally effective, but MSD-0602 didn’t bind to and activate a receptor in cells called PPARγ. Rather, the investigational drug clings to the mitochondria, part of the cell that produces energy.
“The drug altered the cell’s ability to generate energy,” Finck says. “And it also seems to have an anti-inflammatory role in the cell. We also found that the drug improved insulin sensitivity in many different kinds of cells including muscle, fat and liver cells.”
Next, he and his colleagues will attempt to identify proteins that bind to the mitochondrial membrane. Future therapies then could be developed specifically to bind to those proteins while avoiding activation of the PPARγ pathway.
“During the last few years there has been some hesitation in the drug-development business about targeting PPARγ based on what we’ve learned about side effects from drugs that regulate that pathway,” Finck says. “So the biologist in me is very interested in identifying other targets for diabetes drugs and understanding their role in regulating metabolism.”
Meanwhile, Metabolic Solutions is testing the investigational drug in patients as part of phase II clinical trials to learn how well it controls their blood glucose.